FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983526026> ?p ?o ?g. }

• W1983526026 endingPage "2805" @default.
• W1983526026 startingPage "2805" @default.
• W1983526026 abstract "Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials.To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS).Randomized, open label, blinded end point study of 22 576 hypertensive CAD patients aged 50 years or older, which was conducted September 1997 to February 2003 at 862 sites in 14 countries.Patients were randomly assigned to either CAS (verapamil sustained release) or NCAS (atenolol). Strategies specified dose and additional drug regimens. Trandolapril and/or hydrochlorothiazide was administered to achieve blood pressure goals according to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) of less than 140 mm Hg (systolic) and less than 90 mm Hg (diastolic); and less than 130 mm Hg (systolic) and less than 85 mm Hg (diastolic) if diabetes or renal impairment was present. Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment.Primary: first occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months.At 24 months, in the CAS group, 6391 patients (81.5%) were taking verapamil sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide. In the NCAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trandolapril. After a follow-up of 61 835 patient-years (mean, 2.7 years per patient), 2269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in CAS and 10.17% in NCAS; relative risk [RR], 0.98; 95% confidence interval [CI], 0.90-1.06). Two-year blood pressure control was similar between groups. The JNC VI blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of CAS and 64.0% (systolic) and 88.1% (diastolic) of NCAS patients. A total of 71.7% of CAS and 70.7% of NCAS patients achieved a systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg.The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients." @default.
• W1983526026 created "2016-06-24" @default.
• W1983526026 creator A5001241147 @default.
• W1983526026 creator A5003816226 @default.
• W1983526026 creator A5011695335 @default.
• W1983526026 creator A5012514694 @default.
• W1983526026 creator A5015997825 @default.
• W1983526026 creator A5021945153 @default.
• W1983526026 creator A5028424707 @default.
• W1983526026 creator A5036777161 @default.
• W1983526026 creator A5041291525 @default.
• W1983526026 creator A5058789020 @default.
• W1983526026 creator A5061196407 @default.
• W1983526026 creator A5062463658 @default.
• W1983526026 creator A5065188755 @default.
• W1983526026 creator A5069393683 @default.
• W1983526026 creator A5082898423 @default.
• W1983526026 creator A5084756058 @default.
• W1983526026 date "2003-12-03" @default.
• W1983526026 modified "2023-10-16" @default.
• W1983526026 title "A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease" @default.
• W1983526026 cites W1579185299 @default.
• W1983526026 cites W180946569 @default.
• W1983526026 cites W1970398986 @default.
• W1983526026 cites W2012481262 @default.
• W1983526026 cites W2049397775 @default.
• W1983526026 cites W2056976690 @default.
• W1983526026 cites W2057176689 @default.
• W1983526026 cites W2074411241 @default.
• W1983526026 cites W2085293694 @default.
• W1983526026 cites W2085609603 @default.
• W1983526026 cites W2088581697 @default.
• W1983526026 cites W2102979143 @default.
• W1983526026 cites W2106073810 @default.
• W1983526026 cites W2109861453 @default.
• W1983526026 cites W2116620721 @default.
• W1983526026 cites W2118194784 @default.
• W1983526026 cites W2120235169 @default.
• W1983526026 cites W2133217116 @default.
• W1983526026 cites W2137408480 @default.
• W1983526026 cites W2139805666 @default.
• W1983526026 cites W2146851676 @default.
• W1983526026 cites W2152548271 @default.
• W1983526026 cites W2156121263 @default.
• W1983526026 cites W2165141146 @default.
• W1983526026 cites W2189592079 @default.
• W1983526026 cites W2296998040 @default.
• W1983526026 cites W2312999996 @default.
• W1983526026 cites W2318469372 @default.
• W1983526026 cites W2318628277 @default.
• W1983526026 cites W2341695455 @default.
• W1983526026 cites W2414167269 @default.
• W1983526026 cites W567316860 @default.
• W1983526026 cites W2003670762 @default.
• W1983526026 cites W2026073799 @default.
• W1983526026 doi "https://doi.org/10.1001/jama.290.21.2805" @default.
• W1983526026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14657064" @default.
• W1983526026 hasPublicationYear "2003" @default.
• W1983526026 type Work @default.
• W1983526026 sameAs 1983526026 @default.
• W1983526026 citedByCount "1185" @default.
• W1983526026 countsByYear W19835260262012 @default.
• W1983526026 countsByYear W19835260262013 @default.
• W1983526026 countsByYear W19835260262014 @default.
• W1983526026 countsByYear W19835260262015 @default.
• W1983526026 countsByYear W19835260262016 @default.
• W1983526026 countsByYear W19835260262017 @default.
• W1983526026 countsByYear W19835260262018 @default.
• W1983526026 countsByYear W19835260262019 @default.
• W1983526026 countsByYear W19835260262020 @default.
• W1983526026 countsByYear W19835260262021 @default.
• W1983526026 countsByYear W19835260262022 @default.
• W1983526026 countsByYear W19835260262023 @default.
• W1983526026 crossrefType "journal-article" @default.
• W1983526026 hasAuthorship W1983526026A5001241147 @default.
• W1983526026 hasAuthorship W1983526026A5003816226 @default.
• W1983526026 hasAuthorship W1983526026A5011695335 @default.
• W1983526026 hasAuthorship W1983526026A5012514694 @default.
• W1983526026 hasAuthorship W1983526026A5015997825 @default.
• W1983526026 hasAuthorship W1983526026A5021945153 @default.
• W1983526026 hasAuthorship W1983526026A5028424707 @default.
• W1983526026 hasAuthorship W1983526026A5036777161 @default.
• W1983526026 hasAuthorship W1983526026A5041291525 @default.
• W1983526026 hasAuthorship W1983526026A5058789020 @default.
• W1983526026 hasAuthorship W1983526026A5061196407 @default.
• W1983526026 hasAuthorship W1983526026A5062463658 @default.
• W1983526026 hasAuthorship W1983526026A5065188755 @default.
• W1983526026 hasAuthorship W1983526026A5069393683 @default.
• W1983526026 hasAuthorship W1983526026A5082898423 @default.
• W1983526026 hasAuthorship W1983526026A5084756058 @default.
• W1983526026 hasConcept C126322002 @default.
• W1983526026 hasConcept C134018914 @default.
• W1983526026 hasConcept C164705383 @default.
• W1983526026 hasConcept C27016395 @default.
• W1983526026 hasConcept C2776525901 @default.
• W1983526026 hasConcept C2778198053 @default.
• W1983526026 hasConcept C2778213512 @default.
• W1983526026 hasConcept C2778425758 @default.

• next